Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2870 (LINC02870)
- Target
- LINC02870
- Molecular classification
- Long non-coding RNA (lncRNA), Long intergenic non-coding RNA (lincRNA), Non-coding RNA-derived small protein (ERSP), Other
01
Overview
Long intergenic non-protein coding RNA 2870 (LINC02870) is a non-coding RNA gene located on human chromosome 10 (C10orf91) that encodes a small protein, ERSP. LINC02870/ERSP is highly expressed in triple-negative breast cancer tissues, contributing to cancer progression by inducing ER stress and activating the IRE1α/XBP1s branch of the unfolded protein response, promoting nuclear accumulation of XBP1s and expression of stress-response genes. Elevated levels of LINC02870 or ERSP are associated with poor cancer prognosis, making them potential therapeutic targets and biomarkers. LINC02870 joins the growing list of lncRNAs and lincRNAs shown to encode functional peptides/proteins with roles in gene regulation and disease context. If further structure or drug response is needed, refer to the latest experimental data in peer-reviewed literature for additional therapeutic validation.
- Other names
- bA432J24.4C10orf91uncharacterized protein C10orf91ERSP
02
Mechanism of action
null (no characterized mechanism for drugs, as the target is novel and not yet pharmacologically exploited)
03
Biological functions
Regulation of chromatin architectureRegulation of transcriptionEnhancement of unfolded protein response (UPR)Modulation of ER stressPromotion of cell proliferation (in tumors)Promotion of metastasisOther (potential roles may extend to RNA stabilization and enhancer-associated activity, per lincRNA family properties)
04
Disease associations
CancerTriple-negative breast cancer progressionHepatocellular carcinoma metastasisOther (possible, given the emerging functional insights with lncRNAs and lincRNAs in disease biology)
05
Safety considerations
As with most lncRNA/protein targets, therapeutic targeting may present off-target or tissue-specific expression risks, though no specific safety challenges are characterized in literature for LINC02870 or ERSP.
06
Interacting drugs
No direct drugs are currently described as interacting with LINC02870 or ERSP in published literature.
1 more in the full profile.
07
Biomarkers
Elevated expression of LINC02870 or ERSP correlates with poor prognosis in triple-negative breast cancer patients, suggesting potential as diagnostic or prognostic biomarkers.Other (uncharacterized; more studies needed, typical for emerging lincRNAs)
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 2870 (LINC02870).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2870 (LINC02870).